CAR-T Cell Therapy for ALL

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and the second most frequent acute leukemia in adults. B-cell ALL constitutes approximately 85% of all ALL diagnoses. In Pakistan, ALL represents the most prevalent haematological malignancy presenting to tertiary centres, with AFBMTC receiving the largest national referral volume for haematological malignancies and transplantation. First-line combination chemotherapy achieves complete remission (CR) in \>95% of paediatric patients; however, 15-20% relapse. Outcomes following first relapse are substantially inferior:

Trial Details

NCT ID
NCT07695012
Phase
EARLY_PHASE1
Sponsor
Dr. Zaineb Akram
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CAR-T cell infusion
Locations (sample)
  • Rawalpindi, Pakistan|33.59733,73.0479

Key Eligibility Criteria

  • Inclusion Criteria
  • All of the following criteria must be met for enrolment:
  • 1\. Age ≥5 years and ≤50 years at the time of consent
  • 2\. Morphologically or immunophenotypically confirmed B-cell ALL (CD19+) meeting one or more of the following relapsed/refractory criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →